JP2020522508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522508A5 JP2020522508A5 JP2019566619A JP2019566619A JP2020522508A5 JP 2020522508 A5 JP2020522508 A5 JP 2020522508A5 JP 2019566619 A JP2019566619 A JP 2019566619A JP 2019566619 A JP2019566619 A JP 2019566619A JP 2020522508 A5 JP2020522508 A5 JP 2020522508A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- antibody according
- subject
- identified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127759A JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2025281525A JP2026053613A (ja) | 2017-06-01 | 2025-12-25 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513831P | 2017-06-01 | 2017-06-01 | |
| US62/513,831 | 2017-06-01 | ||
| PCT/US2018/035670 WO2018223040A1 (en) | 2017-06-01 | 2018-06-01 | Methods of treating a tumor using an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127759A Division JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522508A JP2020522508A (ja) | 2020-07-30 |
| JP2020522508A5 true JP2020522508A5 (enExample) | 2021-07-26 |
| JP7780857B2 JP7780857B2 (ja) | 2025-12-05 |
Family
ID=62685228
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566619A Active JP7780857B2 (ja) | 2017-06-01 | 2018-06-01 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2023127759A Pending JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2025281525A Pending JP2026053613A (ja) | 2017-06-01 | 2025-12-25 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127759A Pending JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2025281525A Pending JP2026053613A (ja) | 2017-06-01 | 2025-12-25 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11566073B2 (enExample) |
| EP (1) | EP3630840A1 (enExample) |
| JP (3) | JP7780857B2 (enExample) |
| KR (2) | KR20240149982A (enExample) |
| CN (2) | CN117462668A (enExample) |
| WO (1) | WO2018223040A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| EP3288980B1 (en) | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| EP3630840A1 (en) | 2017-06-01 | 2020-04-08 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-pd-1 antibody |
| US12668635B1 (en) | 2017-11-21 | 2026-06-30 | Arcus Biosciences, Inc. | Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof |
| SG11202007590TA (en) * | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| JP2022514952A (ja) * | 2018-12-19 | 2022-02-16 | ストラータ オンコロジー， インコーポレイテッド | チェックポイント阻害薬応答性がんを有する対象を検出及び処置する方法 |
| MX2021013222A (es) * | 2019-05-03 | 2022-01-06 | Genentech Inc | Metodos para tratar el cancer con un anticuerpo anti-pd-l1. |
| US12275986B2 (en) * | 2020-01-06 | 2025-04-15 | Duke University | Biomarkers associated with checkpoint immune therapy and methods of using same |
| CN110923329B (zh) * | 2020-02-06 | 2020-05-12 | 至本医疗科技（上海）有限公司 | Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| CN111440822A (zh) * | 2020-04-16 | 2020-07-24 | 苏州大学附属第二医院 | 一种突变lats1质粒的构建与应用 |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| CN112961920A (zh) * | 2021-03-24 | 2021-06-15 | 臻和(北京)生物科技有限公司 | 一种预测肝胆肿瘤患者免疫检查点抑制剂联合靶向治疗疗效的方法及产品 |
| JP7806990B2 (ja) * | 2021-08-10 | 2026-01-27 | 国立大学法人 新潟大学 | 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法 |
| CN113943806A (zh) * | 2021-11-04 | 2022-01-18 | 至本医疗科技（上海）有限公司 | 预测肺腺癌患者对免疫疗法敏感性的生物标志物、应用和装置 |
| WO2023209035A1 (en) * | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Methods and systems for predicting cancer therapy response |
| CN114931637B (zh) * | 2022-06-27 | 2025-02-18 | 中山大学中山眼科中心 | Pdl1抗体在角膜新生血管疾病中的应用 |
| CN115825441B (zh) * | 2023-01-30 | 2023-05-26 | 上海秤信生物科技有限公司 | 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物 |
| AU2024362581A1 (en) * | 2023-10-19 | 2026-04-30 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 agents |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| CN106062004A (zh) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| US20170175197A1 (en) * | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| EP3134546A4 (en) * | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| WO2016191751A1 (en) * | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| AU2016315878A1 (en) | 2015-09-03 | 2018-03-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| KR20250107295A (ko) | 2016-06-03 | 2025-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체 |
| EP3630840A1 (en) | 2017-06-01 | 2020-04-08 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-pd-1 antibody |
| CN109528743A (zh) * | 2018-12-14 | 2019-03-29 | 青岛大学 | 对非小细胞肺癌抑癌基因stk11突变敏感的药物及其筛选方法 |
| CN113249483B (zh) * | 2021-06-10 | 2021-10-08 | 北京泛生子基因科技有限公司 | 一种检测肿瘤突变负荷的基因组合、系统及应用 |
-
2018
- 2018-06-01 EP EP18733121.0A patent/EP3630840A1/en active Pending
- 2018-06-01 US US16/617,725 patent/US11566073B2/en active Active
- 2018-06-01 KR KR1020247032911A patent/KR20240149982A/ko active Pending
- 2018-06-01 CN CN202311104154.0A patent/CN117462668A/zh active Pending
- 2018-06-01 JP JP2019566619A patent/JP7780857B2/ja active Active
- 2018-06-01 CN CN201880035434.1A patent/CN110678483B/zh active Active
- 2018-06-01 KR KR1020197038639A patent/KR102714702B1/ko active Active
- 2018-06-01 WO PCT/US2018/035670 patent/WO2018223040A1/en not_active Ceased
-
2023
- 2023-01-30 US US18/161,713 patent/US12227576B2/en active Active
- 2023-08-04 JP JP2023127759A patent/JP2023159179A/ja active Pending
-
2025
- 2025-01-09 US US19/015,341 patent/US20250145713A1/en active Pending
- 2025-12-25 JP JP2025281525A patent/JP2026053613A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | The role of poly (ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review | |
| Zhou et al. | Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies | |
| Xie et al. | KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup | |
| Jin et al. | Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy | |
| Awad et al. | Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis | |
| Lamberti et al. | Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer | |
| Beaver et al. | PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system | |
| Schmitt et al. | ATM deficiency is associated with sensitivity to PARP1-and ATR inhibitors in lung adenocarcinoma | |
| Pu et al. | Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance | |
| Becker et al. | Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment | |
| JP2013523744A5 (enExample) | ||
| JP2017214436A5 (enExample) | ||
| Nelson et al. | Implications of DNA damage and DNA repair on human diseases | |
| Bush et al. | AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models | |
| ES2686549T3 (es) | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer | |
| Qin et al. | Basket trials for intractable cancer | |
| Xue et al. | Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma | |
| CN115998872A (zh) | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 | |
| Cui et al. | Expert opinion on translational research for advanced glioblastoma treatment | |
| He et al. | Alpha thalassemia/mental retardation syndrome X-linked, the alternative lengthening of telomere phenotype, and gliomagenesis: current understandings and future potential | |
| JP2022531980A5 (enExample) | ||
| Xiong et al. | Comutations in DDR pathways predict atezolizumab response in non-small cell lung cancer patients | |
| Li et al. | Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives | |
| Wang et al. | The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants. | |
| JP2024521696A5 (enExample) |